Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 1-Year Low – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares hit a new 52-week low on Friday . The company traded as low as $37.18 and last traded at $37.80, with a volume of 15660 shares changing hands. The stock had previously closed at $57.67.

Analysts Set New Price Targets

Several research firms have recently commented on ZLDPF. BTIG Research raised Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday. Four equities research analysts have rated the stock with a Strong Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Zealand Pharma A/S currently has an average rating of “Buy”.

Zealand Pharma A/S Price Performance

The company has a quick ratio of 14.10, a current ratio of 14.10 and a debt-to-equity ratio of 0.02. The company has a market cap of $2.60 billion, a price-to-earnings ratio of 2.67 and a beta of 0.75. The company has a fifty day simple moving average of $64.96 and a two-hundred day simple moving average of $70.77.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.34) by $0.53. The business had revenue of $10.79 million during the quarter, compared to the consensus estimate of $19.69 million. Zealand Pharma A/S had a return on equity of 49.76% and a net margin of 70.06%. On average, equities research analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.